Exact Mass: 437.10490380000005
Exact Mass Matches: 437.10490380000005
Found 201 metabolites which its exact mass value is equals to given mass value 437.10490380000005
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Flavopiridol HCl
C21H21Cl2NO5 (437.07967160000004)
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent D006133 - Growth Substances > D006131 - Growth Inhibitors D000970 - Antineoplastic Agents
7-(1,2,3,4,4a,5,7,7a-Octahydropyrrolo[3,4-b]pyridin-6-yl)-1-cyclopropyl-6-fluoranyl-8-methoxy-4-oxidanylidene-quinoline-3-carboxylic acid hydrochloride
C21H25ClFN3O4 (437.15175320000003)
3-Phenylpropyl glucosinolate
3-Phenylpropyl glucosinolate is found in brassicas. 3-Phenylpropyl glucosinolate is present in horseradish (Armoracia lapathifolia). Present in horseradish (Armoracia lapathifolia). 3-Phenylpropyl glucosinolate is found in horseradish and brassicas.
(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine
(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine is a metabolite of aprepitant. Aprepitant (Emend) is an antiemetic chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by blocking the neurokinin 1 (NK1) receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003. (Wikipedia)
N-(4-(2-Chlorophenyl)-6,7-dimethyl-3-quinolyl)-N'-(2,4-difluorophenyl)urea
C24H18ClF2N3O (437.11063920000004)
N-Acetylcochinol-O-phosphate
Aleglitazar
C24H23NO5S (437.12968680000006)
2-[6,8-Dichloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylacetamide
C21H22Cl3N3O (437.08283720000003)
Estromustine
C23H29Cl2NO3 (437.15243840000005)
Isavuconazole
C22H17F2N5OS (437.11218160000004)
Ravuconazole
C22H17F2N5OS (437.11218160000004)
Ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate
C20H24ClN3O4S (437.1175974000001)
N-[2-[(R)-[3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-pyrrol-3-yl]benzamide
C20H18F3N3O3S (437.10209140000006)
jatropham 5-O-3)-beta-D-glucopyranoside>|Jatropham 5-O-beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranoside
(3S,4R,5S)-4-ethenyl-3-(beta-D-glucopyranosyloxy)-4,4a,5,6,7,8-hexahydro-8-oxo-3H-pyrano[3,4-c]pyridine-6-sulfonic acid
Hysco
C17H21NO4.BrH.3H2O (437.10490380000005)
Scopolamine hydrobromide trihydrate appears as white orthorhombic sphenoidal crystals from water. pH of 0.05 molar solution: 5.85. (NTP, 1992) Scopolamine hydrobromide trihydrate is a hydrate that is the trihydrate form of scopolamine hydrobromide. It has a role as a mydriatic agent, a muscarinic antagonist, an anaesthesia adjuvant, an antispasmodic drug and an antiemetic. It contains a scopolamine hydrobromide (anhydrous). Scopolamine Hydrobromide is the hydrobromide salt form of scopolamine, a tropane alkaloid derived from plants of the nightshade family (Solanaceae), specifically Hyoscyamus niger and Atropa belladonna, with anticholinergic, antiemetic and antivertigo properties. Structurally similar to acetylcholine, scopolamine antagonizes acetylcholine activity mediated by muscarinic receptors located on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. The agent is used to cause mydriasis, cycloplegia, to control the secretion of saliva and gastric acid, to slow gut motility, and prevent vomiting. An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic. C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D009184 - Mydriatics C78283 - Agent Affecting Organs of Special Senses > C29706 - Mydriatic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents
Ala Cys Met Asn
Ala Cys Asn Met
Ala Met Cys Asn
Ala Met Asn Cys
Ala Asn Cys Met
Ala Asn Met Cys
Cys Ala Met Asn
Cys Ala Asn Met
Cys Cys Gly Arg
Cys Cys Asn Val
Cys Cys Arg Gly
Cys Cys Val Asn
Cys Asp Asn Ser
Cys Asp Ser Asn
Cys Gly Cys Arg
Cys Gly Met Gln
Cys Gly Gln Met
Cys Gly Arg Cys
Cys Met Ala Asn
Cys Met Gly Gln
Cys Met Asn Ala
Cys Met Gln Gly
Cys Asn Ala Met
Cys Asn Cys Val
Cys Asn Asp Ser
Cys Asn Met Ala
Cys Asn Ser Asp
Cys Asn Val Cys
Cys Gln Gly Met
Cys Gln Met Gly
Cys Arg Cys Gly
Cys Arg Gly Cys
Cys Ser Asp Asn
Cys Ser Asn Asp
Cys Val Cys Asn
Cys Val Asn Cys
Asp Cys Asn Ser
Asp Cys Ser Asn
Asp Asn Cys Ser
Asp Asn Ser Cys
Asp Ser Cys Asn
Asp Ser Asn Cys
Gly Cys Cys Arg
Gly Cys Met Gln
Gly Cys Gln Met
Gly Cys Arg Cys
Gly Met Cys Gln
Gly Met Gln Cys
Gly Gln Cys Met
Gly Gln Met Cys
Gly Arg Cys Cys
Met Ala Cys Asn
Met Ala Asn Cys
Met Cys Ala Asn
Met Cys Gly Gln
Met Cys Asn Ala
Met Cys Gln Gly
Met Gly Cys Gln
Met Gly Gln Cys
Met Asn Ala Cys
Met Asn Cys Ala
Met Gln Cys Gly
Met Gln Gly Cys
Asn Ala Cys Met
Asn Ala Met Cys
Asn Cys Ala Met
Asn Cys Cys Val
Asn Cys Asp Ser
Asn Cys Met Ala
Asn Cys Ser Asp
Asn Cys Val Cys
Asn Asp Cys Ser
Asn Asp Ser Cys
Asn Met Ala Cys
Asn Met Cys Ala
Asn Ser Cys Asp
Asn Ser Asp Cys
Asn Val Cys Cys
Gln Cys Gly Met
Gln Cys Met Gly
Gln Gly Cys Met
Gln Gly Met Cys
Gln Met Cys Gly
Gln Met Gly Cys
Arg Cys Cys Gly
Arg Cys Gly Cys
Arg Gly Cys Cys
Ser Cys Asp Asn
Ser Cys Asn Asp
Ser Asp Cys Asn
Ser Asp Asn Cys
Ser Asn Cys Asp
Ser Asn Asp Cys
Val Cys Cys Asn
Val Cys Asn Cys
Val Asn Cys Cys
Nap-Asn-OH
C22H19N3O7 (437.12229440000004)
Asn-Nap-OH
C22H19N3O7 (437.12229440000004)
3-Phenylpropyl glucosinolate
Moxifloxacin HCl
C21H25ClFN3O4 (437.15175320000003)
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
[(2R,3S,4R,5R,6R)-3,4-diacetyloxy-5-(1,3-dioxoisoindol-2-yl)-6-fluorooxan-2-yl]methyl acetate
C20H20FNO9 (437.11220420000006)
Ravuconazole
C22H17F2N5OS (437.11218160000004)
C254 - Anti-Infective Agent > C514 - Antifungal Agent
(4-nitrophenyl) (2S)-6-amino-2-(phenylmethoxycarbonylamino)hexanoate,hydrochloride
C20H24ClN3O6 (437.13535540000004)
(4E)-5-{4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl}-(3S)-3-hydroxy-4-pentenoic acid
C20H24FN3O5S (437.14206260000003)
4-[(2-chloro-4,6-dinitrophenyl)azo]-N,N-diethyl-2,5-dimethoxyaniline
C18H20ClN5O6 (437.11020500000006)
methyl 4-[1-[[(2,4-dichlorophenyl)amino]carbonyl]-3,3-dimethyl-2-oxobutoxy]benzoate
C21H21Cl2NO5 (437.07967160000004)
O,O-Diethylphosphoryl (Z)-2-(2-aminothiazol-4-yl)-2-(tert-Butoxycarbonylmethoxyimino)acetate
C15H24N3O8PS (437.10216740000004)
N-ALPHA-DANSYL-L-TRYPTOPHAN CYCLOHEXYLAMMONIUM SALT
C23H23N3O4S (437.14091980000006)
(2S,3R)-2-((S)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)Morpholine
2-Thiophenecarboxamide, 5-chloro-N-[3-[[3,5-dimethyl-4-(3-oxo-4-morpholinyl)phenyl]amino]-2-hydroxypropyl]
C20H24ClN3O4S (437.1175974000001)
Cimetropium bromide
C21H28BrNO4 (437.12015880000007)
Cimetropium Bromide (DA-3177) is a mAChR antagonist for long-term treatment of irritable bowel syndrome.
Aleglitazar
C24H23NO5S (437.12968680000006)
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-2,6-difluoro-alpha-methyl-L-phenylalanine
N,N-Bis(4-sulfobutyl)-3,5-dimethylaniline disodium salt
Fominoben hydrochloride
(R)-3-((((9H-FLUOREN-9-YL)METHOXY)CARBONYL)AMINO)-4-(3,4-DIFLUOROPHENYL)BUTANOIC ACID
LY 2119620
C19H24ClN5O3S (437.1288304000001)
LY2119620 is a high-affinity muscarinic M2/M4 receptor agonist.
Fmoc-(S)-3-Amino-4-(3,4-Difluoro-Phenyl)-Butyric Acid
Colazal
D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D005765 - Gastrointestinal Agents D018501 - Antirheumatic Agents
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (1:1), rel-
C21H25ClFN3O4 (437.15175320000003)
2-DEOXY-2-PHTHALIMIDO-3,4,6-TRI-O-ACETYL-ALPHA-D-GALACTOPYRANOSYL FLUORIDE
C20H20FNO9 (437.11220420000006)
(2R,3S)-2-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholine
(2R)-3-(3-chloro-4-hydroxyphenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
C24H20ClNO5 (437.1029940000001)
Isavuconazole
C22H17F2N5OS (437.11218160000004)
J - Antiinfectives for systemic use > J02 - Antimycotics for systemic use > J02A - Antimycotics for systemic use > J02AC - Triazole and tetrazole derivatives D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent
4-(4-Chloro-3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxamido)-2,6-difluorobenzoic acid
C22H22ClF2NO4 (437.12053460000004)
C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids
N-Acetylcochinol-O-phosphate
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
Ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate
C20H24ClN3O4S (437.1175974000001)
2-Chloro-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-5-diethylsulfamoyl-benzamide
C19H20ClN3O3S2 (437.06345600000003)
Ipsapirone hydrochloride
C19H24ClN5O3S (437.1288304000001)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist
2-[6,8-Dichloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylacetamide
C21H22Cl3N3O (437.08283720000003)
2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid
C24H23NO5S (437.12968680000006)
4-(Carbamoylamino)benzoic acid [2-(3-chloro-4-methylanilino)-2-oxo-1-phenylethyl] ester
C23H20ClN3O4 (437.1142270000001)
2-chloro-5-(diethylsulfamoyl)-N-(2-methyl-1,3-benzothiazol-6-yl)benzamide
C19H20ClN3O3S2 (437.06345600000003)
N-Acetylcochinol-O-phosphate
(E)-1-(glutathion-S-yl)-N-hydroxy-omega-(methylsulfanyl)butan-1-imine
3,5,7,9,11,13,15,17,19-Nonaoxoicosanoate
C20H21O11- (437.10838160000003)
10-[(2R,3R)-2,3-dihydroxy-3-[(4S)-2-oxido-2-oxo-1,3,2lambda5-dioxaphospholan-4-yl]propyl]-7,8-dimethylbenzo[g]pteridine-2,4-dione
C17H18N4O8P- (437.08622180000003)
N-[2-[(R)-[3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-pyrrol-3-yl]benzamide
C20H18F3N3O3S (437.10209140000006)
(RS)-alpha-Cyano-3-phenoxybenzyl (RS)-2,2-dichloro-1-(4-ethoxyphenyl)cyclopropanecarboxylate
C24H17Cl2NO3 (437.05854320000003)
Cladoniamide A
C22H16ClN3O5 (437.07784360000005)
An organic heterohexacyclic compound that is cladoniamide B in which the chlorine attached to the methoxy-bearing indole moiety is replaced by a hydrogen. It has been isolated from the culture broth of Streptomyces uncialis.
4-[5-(3-Methoxyphenyl)-3-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide
C23H23N3O4S (437.14091980000006)
4-({[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]methylene}amino)-5-(4-pyridinyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
C24H19N7S (437.14225740000006)
N-[1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinyl]carbamic acid tert-butyl ester
N-(1,3-benzodioxol-5-yl)-2-[4-(4-chlorophenyl)sulfonyl-1-piperazinyl]acetamide
C19H20ClN3O5S (437.0812140000001)
6-[2-(2-methoxyphenyl)imino-3-(2-oxolanylmethyl)-4-thiazolyl]-4H-1,4-benzoxazin-3-one
C23H23N3O4S (437.14091980000006)
N4-cyclohexyl-N1-ethyl-N4-(2-pyridinylmethyl)benzene-1,4-disulfonamide
C20H27N3O4S2 (437.14429020000006)
2-[7-chloro-2,3-dioxo-4-(phenylmethyl)-1-quinoxalinyl]-N-(3-fluorophenyl)acetamide
5-Nitro-2-furancarboxylic acid [2-oxo-2-[3-(1-piperidinylsulfonyl)anilino]ethyl] ester
N-[2-(3-chlorophenyl)ethyl]-2-[[3-cyano-6-(3-methoxyphenyl)-2-pyridinyl]thio]acetamide
C23H20ClN3O2S (437.09646900000007)
N-(5-phenyl-1,3,4-thiadiazol-2-yl)-2-[[4-propyl-5-(2-pyridinyl)-1,2,4-triazol-3-yl]thio]acetamide
(4-Difluoromethoxy-benzylidene)-[6-(4-difluoromethoxy-phenyl)-2,3-dihydro-imidazo[2,1-b]thiazol-5-yl]-amine
1-(4-fluorophenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea
C23H20FN3O3S (437.1209342000001)
6-O-benzyl-2-deoxyguanosine 5-monophosphate
C17H20N5O7P (437.11003000000005)
2-[(1S,3R,4aR,9aS)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]acetic acid
C20H20FNO7S (437.09444620000005)
2-[(1R,3R,4aR,9aS)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
C20H20FNO7S (437.09444620000005)
2-[(1R,3S,4aS,9aR)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
C20H20FNO7S (437.09444620000005)
2-[(1S,3S,4aS,9aR)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
C20H20FNO7S (437.09444620000005)
3-(3,4-dimethoxyphenyl)-N-{2-[3-methoxy-4-(sulfooxy)phenyl]ethyl}prop-2-enimidic acid
C20H23NO8S (437.11443180000003)
GW438014A
C23H23N3O4S (437.14091980000006)
GW438014A is a potent and selective NPY-Y5 receptor antagonist. GW438014A inhibits food intake and reduces body weight gain in obese rodents[1].
3-(3,5-dichloro-2-hydroxy-6-methoxy-4-methylphenyl)-4-(3-methylbut-2-en-1-yl)-3h-isoindole-1,5,7-triol
C21H21Cl2NO5 (437.07967160000004)
7-chloro-11,15-dihydroxy-23-methoxy-13-methyl-3,13,16-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(23),2(10),4,6,8,17,19,21-octaene-12,14-dione
C22H16ClN3O5 (437.07784360000005)
2-amino-n-(1-{[3-(dichloromethyl)-6,8-dihydroxy-3-methyl-1-oxo-4a,5,6,7-tetrahydro-4h-2-benzopyran-4-yl]-c-hydroxycarbonimidoyl}ethyl)propanimidic acid
C17H25Cl2N3O6 (437.11203300000005)